Najat Khan is CEO & President at RECURSION PHARMACEUTICALS, INC. (RXRX). They have made 2 open-market trades across 1 company since 2025, most recently 2026-09-08.
CIK 0002020969
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| RXRX | 2,072,890 | $7.2M |
Shares reported on the most recent Form 4, priced at the 2026-09-10 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RXRX | SELL · 10b5-1 | 2026-09-08 | 2026-09-10 | $3.52 | $79K | +26.0% | +24.6% | — |
| RXRX | SELL · 10b5-1 | 2026-06-05 | 2026-06-05 | $3.58 | $84K | -8.5% | +16.0% | +0.9% |
| RXRX | SELL | 2026-03-09 | 2026-03-11 | $3.35 | $95K | -5.0% | -3.5% | -5.1% |
| RXRX | SELL · 10b5-1 | 2025-12-22 | 2025-12-29 | $4.41 | $1.1M | +12.3% | +7.7% | -31.6% |
| RXRX | SELL | 2025-08-18 | 2025-08-19 | $5.52 | $404K | -6.2% | -1.6% | -17.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.